Program Schedule

33
New Frontiers in Influenza

Thursday, October 9, 2014: 10:30 AM-12:00 PM
Room: The Pennsylvania Convention Center: 118-ABC

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe the epidemiology and virological characteristics of influenza viruses with pandemic potential and why public health offices are concerned about them
  • describe the wide variety of influenza vaccines that are currently available and be able to determine which vaccines should be used for different patients
  • differentiate among the currently available antiviral agents and other treatments, who should receive them, and describe interventions that may be available in the near future

Target Audience: Vaccinologists, Scientists, Researchers, Public health practitioners, Pharmacists, Nurses, Members-in-training, Infectious diseases physicians, Infectious diseases pediatricians, Infection preventionists, Hospital epidemiologists, Fellows, Epidemiologists, Clinicians, Academicians

Tracks: Pediatric ID, Global ID, Epidemiology and Infection Control, Adult ID

Moderators:  David L. Swerdlow, MD, Centers for Disease Control and Prevention and Janet a. Englund, MD, FIDSA, Seattle Children's Hospital

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-14-104-L01-P

Disclosures:

D. L. Swerdlow, None

J. A. Englund, Gilead: Consultant and Investigator, Consulting fee and Research support
Chimerix: Investigator, Research support
Roche: Investigator, Research support
GlaxoSmithKline: Consultant, Investigator and Member, DSMB (DataSafety Monitoring Board), Consulting fee, Payment for DSMB participation and Research support
Ansun Biopharma: Investigator, Research support

M. A. Widdowson, None

F. Hayden, Multiple companies developing or marketing influenza antivirals since 2008 (Abbott, Adamas, Alios, AVI BioPharma, Biocryst, Boehringer-Ingelheim, Contrafect, Crucell, Farmak, GSK, Inhibikase, Janssen, Kirin, Liquidia, Medivector, Nexbio, Respivert, Roche,: Non-paid consultant, No compensation
GSK: Consultant and Topic- respiratory virus vaccines, Honorarium paid to University of Virginia
Sanofi-Pasteur: Member DSMB for vaccine clinical trial, Honorarium paid to University of Virginia
Hologic: Consultant and Topic- respiratory virus diagnostics, Honorarium paid to University of Virginia
Law firms (several): Legal testimony, Fees paid to me and to University of Virginia

A. M. Fry, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek